Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy

References

• Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation. 2017;135:e1054–e1091.
   PubMed Web of Science ®Google Scholar
• Silver MA, Maisel A, Yancy CW, et al. BNP consensus panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10:1–30.
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240–e319.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136:e137–e161.
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–e194.
   PubMed Web of Science ®Google Scholar
• Maisel A. Biomarkers in heart failure. Does prognostic utility translate to clinical futility? J Am Coll Cardiol. 2007;50:1061–1063.
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287–296.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24:1710–1718.
   PubMed Web of Science ®Google Scholar
• Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015–2019.
   PubMed Web of Science ®Google Scholar
• Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91–97.
   PubMed Web of Science ®Google Scholar
• Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the breathing not properly multinational study. Am Heart J. 2006;151:999–1005.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590–1595.
   PubMed Web of Science ®Google Scholar
• Clerico A, Recchia FA, Passino C, et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol. 2006;290:H17–H29.
   PubMed Web of Science ®Google Scholar
• Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92:843–849.
   PubMed Web of Science ®Google Scholar
• Kemperman H, Van Den Berg M, Kirkels H, et al. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem. 2004;50:1670–1672.
   PubMed Web of Science ®Google Scholar
• Tateyama H, Hino J, Minamino N, et al. Concentrations and molecular forms of human brain natriuretic peptide in plasma. Biochem Biophys Res Commun. 1992;185:760–767.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528–1538.
   PubMed Web of Science ®Google Scholar
• Collins SP, Ronan-Bentle S, Storrow AB. Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea. Ann Emerg Med. 2003;41:532–545.
   PubMed Web of Science ®Google Scholar
• Misono KS, Philo JS, Arakawa T, et al. Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase. Febs J. 2011;278:1818–1829.
   PubMed Web of Science ®Google Scholar
• Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond). 1998;95:519–529.
   PubMed Web of Science ®Google Scholar
• Chen HH, Burnett JC Jr. Clinical application of the natriuretic peptides in heart failure. Eur Heart J Suppl. 2006;8(Suppl E):E18–E25.
   Web of Science ®Google Scholar
• Pandit K, Mukhopadhyay P, Ghosh S, et al. Natriuretic peptides: diagnostic and therapeutic use. Indian J Endocrinol Metab. 2011;15(Suppl 4):S345–S353.
   PubMedGoogle Scholar
• Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 2017;19:167–176.
   PubMed Web of Science ®Google Scholar
• Cruden NL, Fox KA, Ludlam CA, et al. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913–918.
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Charles CJ, Espiner EA, et al. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond). 1996;91:283–291.
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, McEniery CM, Bongaerts KH, et al. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol. 2001;52:159–164.
   PubMed Web of Science ®Google Scholar
• Von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594–605.
   PubMed Web of Science ®Google Scholar
• Lanfear DE, Chow S, Padhukasahasram B, et al. Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail. 2014;20:662–668.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.
   PubMed Web of Science ®Google Scholar
• Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014;44:303–308.
   PubMed Web of Science ®Google Scholar
• Dickey DM, Barbieri KA, McGuirk CM, et al. Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors. Mol Pharmacol. 2010;78:431–435.
   PubMed Web of Science ®Google Scholar
• De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322.
   PubMed Web of Science ®Google Scholar
• Ng LL, Geeranavar S, Jennings SC, et al. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond). 2004;106:129–133.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Neyou A. Comprehensive review of the relative clinical utility of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide assays in cardiovascular disease. Open Heart Fail J. 2009;2:6–17.
   Google Scholar
• Schou M, Gustafsson F, Kistorp CN, et al. Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem. 2007;53:1928–1935.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Sakai H, Ishikawa C, et al. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur J Heart Fail. 2007;9:667–673.
   PubMed Web of Science ®Google Scholar
• Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46:610–620.
   PubMed Web of Science ®Google Scholar
• Ferrandis MJ, Ryden I, Lindahl TL, et al. Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography. Ups J Med Sci. 2013;118:75–79.
   PubMed Web of Science ®Google Scholar
• Balion C, Don-Wauchope A, Hill S, et al. Use of natriuretic peptide measurement in the management of heart failure. Comparative Effectiveness Review No. 126. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-2007-10060-I.) AHRQ Publication No. 13 (14)-EHC118-EF. Rockville, MD: Agency for Healthcare Research and Quality; Nov 2013. [cited 2017 Mar 1]. Available from: https://www.effectivehealthcare.ahrq.gov/ehc/products/328/1754/heart-failure-natriuretic-peptide-report-131119.pdf.
   Google Scholar
• Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta. 2006;369:95–99.
   PubMed Web of Science ®Google Scholar
• Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol. 2005;123:439–445.
   PubMed Web of Science ®Google Scholar
• Luckenbill KN, Christenson RH, Jaffe AS, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC committee for standardization of markers of cardiac damage. Clin Chem. 2008;54:619–621.
   PubMed Web of Science ®Google Scholar
• AxSYM BNP [package insert]. Abbott Park, IL: Abbott Laboratories; 2008.
   Google Scholar
• Triage BNP [package insert]. San Diego, CA: Biosite Incorporated; 2007.
   Google Scholar
• Advia Centaur BNP [package insert]. Tarrytown, NY: Bayer Diagnositics Corporation; 2003.
   Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167.
   PubMed Web of Science ®Google Scholar
• Hill SA, Booth RA, Santaguida PL, et al. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev. 2014;19:421–438.
   PubMed Web of Science ®Google Scholar
• Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–888.
   Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408–2416.
   PubMed Web of Science ®Google Scholar
• Collins SP, Lindsell CJ, Storrow AB, et al. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med. 2006;47:13–18.
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr., Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation. 2002;106:416–422.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis. 2003;41:571–579.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Lloyd-Jones DM, Van Kimmenade RR, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med. 2007;167:400–407.
   PubMed Web of Science ®Google Scholar
• Knudsen CW, Westheim A, Omland T. [B-type natriuretic peptide and clinical judgement in the diagnosis of heart failure in patients presenting with acute dyspnoea]. Tidsskr Nor Laegeforen. 2003;123:2045–2048.
   PubMedGoogle Scholar
• McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10:198–204.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J. 2004;147:1078–1084.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49:1943–1950.
   PubMed Web of Science ®Google Scholar
• Scrutinio D, Mastropasqua F, Guida P, et al. Renal dysfunction and accuracy of N-terminal pro-B-type natriuretic peptide in predicting mortality for hospitalized patients with heart failure. Circ J. 2014;78:2439–2446.
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52:997–1003.
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;119:70.e23-30.
   PubMedGoogle Scholar
• Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832:2442–2450.
   PubMed Web of Science ®Google Scholar
• McLellan J, Heneghan CJ, Perera R, et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database Syst Rev. 2016;12:CD008966.
   PubMedGoogle Scholar
• Brunner-La Rocca HP, Eurlings L, Richards AM, et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail. 2015;17:1252–1261.
   PubMed Web of Science ®Google Scholar
• Schou M, Gustafsson F, Videbaek L, et al. Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). Eur J Heart Fail. 2013;15:818–827.
   PubMed Web of Science ®Google Scholar
• Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 2017;318:713–720.
   Google Scholar
• Felker GM, Ahmad T, Anstrom KJ, et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC Heart Fail. 2014;2:457–465.
   PubMed Web of Science ®Google Scholar
• Ferro CJ, Spratt JC, Haynes WG, et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97:2323–2330.
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial Of Utility In Reducing Events (OVERTURE). Circulation. 2002;106:920–926.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103–111.
   PubMed Web of Science ®Google Scholar
• Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65:1029–1041.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert OpinPharmacother. 2006;7:575–581.
   PubMed Web of Science ®Google Scholar
• Feng L, Karpinski PH, Sutton P, et al. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53:275–276.
   Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062–1073.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol. 2016;68:1476–1488.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Ishizaka Y, Ishiyama Y, et al. Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Hypertens Res. 1996;19:239–245.
   PubMedGoogle Scholar
• Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017;5:471–482.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF). [cited 2017 Sep 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01920711.
   Google Scholar
• Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68:2425–2436.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Choudhary R. Biomarkers in acute heart failure—state of the art. Nat Rev Cardiol. 2012;9:478–490.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Adams K Jr., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824–839.
   PubMed Web of Science ®Google Scholar
• Semenov AG, Katrukha AG. Different susceptibility of B-type natriuretic peptide (BNP) and BNP precursor (proBNP) to cleavage by neprilysin: the N-terminal part does matter. Clin Chem. 2016;62:617–622.
   PubMed Web of Science ®Google Scholar
• Jaffe AS, Apple FS, Mebazaa A, et al. Unraveling N-terminal pro-B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients. Clin Chem. 2015;61:1016–1018.
   PubMed Web of Science ®Google Scholar
• Acute heart failure: diagnosis and management. Clinical guideline [CG187]. National Institute for Health and Care Excellence; [Oct 2014. cited 2017 Mar 1]. Available from: https://www.nice.org.uk/guidance/cg187.
   Google Scholar
• Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.
   Google Scholar
• Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–2174.
   PubMed Web of Science ®Google Scholar
• Mair J, Lindahl B, Giannitsis E, et al. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care? Eur Heart J Acute Cardiovasc Care. 2017;6:321–328.
   PubMed Web of Science ®Google Scholar
• Faggiano P, Valle R, Aspromonte N, et al. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification. Int J Cardiol. 2010;140:88–94.
   PubMed Web of Science ®Google Scholar
• Anand IS, Rector TS, Kuskowski M, et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15:511–518.
   PubMed Web of Science ®Google Scholar
• De Boer RA, Daniels LB, Maisel AS, et al. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559–569.
   PubMed Web of Science ®Google Scholar
• Bošnjak I, Selthofer-Relatić K, Včev A. Prognostic value of galectin-3 in patients with heart failure. Dis Markers. 2015;2015:690205.
   PubMedGoogle Scholar
• McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12:200–210.
   PubMed Web of Science ®Google Scholar
• Iwahana H, Yanagisawa K, Ito-Kosaka A, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. 1999;264:397–406.
   PubMedGoogle Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–2966.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Pascual-Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol. 2015;115:70B–75B.
   PubMed Web of Science ®Google Scholar
• Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684–691.
   PubMed Web of Science ®Google Scholar